Quick Answer
CANNAPHARMARX, INC. reported Net Income Loss of -$11.13 million for the year ending 2025.
- CANNAPHARMARX, INC. showed a decrease of -12.4% in Net Income Loss from 2024 to 2025.
- This data is from CANNAPHARMARX, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$22.9 thousand | Q2 2013: -$24.1 thousand | Q3 2013: -$25.2 thousand | Q1 2014: -$25.6 thousand | Q2 2014: -$153.1 thousand | Q3 2014: -$479.4 thousand | Q1 2015: -$1.66 million | Q2 2015: -$4.13 million | Q3 2015: -$1.71 million | Q1 2016: -$695.5 thousand | Q2 2016: -$240.0 thousand | Q3 2016: -$29.5 thousand | Q1 2017: -$1.7 thousand | Q2 2017: $0.00 | Q3 2017: $0.00 | Q1 2018: $0.00 | Q2 2018: -$70.5 thousand | Q3 2018: -$1.09 million | Q1 2019: -$1.07 million | Q2 2019: -$748.1 thousand | Q3 2019: -$9.32 million | Q1 2020: -$4.21 million | Q2 2020: -$1.47 million | Q3 2020: -$2.65 million | Q1 2021: $1.20 million | Q2 2021: -$1.67 million | Q3 2021: -$1.03 million | Q1 2022: -$2.07 million | Q2 2022: -$1.51 million | Q3 2022: -$1.31 million | Q1 2023: -$1.41 million | Q2 2023: -$1.88 million | Q3 2023: -$564.4 thousand | Q1 2024: -$11.72 million | Q2 2024: $5.36 million | Q3 2024: $188.4 thousand | Q4 2024: -$3.74 million | Q1 2025: -$690.6 thousand | Q2 2025: -$1.41 million | Q3 2025: -$1.48 million.
- Over the full 16 years of available data (2010 to 2025), CANNAPHARMARX, INC.'s Net Income Loss has declined by 2,034.5%.
- Historical annual values: Fiscal year 2025: -$11.13 million | Fiscal year 2024: -$9.91 million | Fiscal year 2023: $3.69 million | Fiscal year 2022: -$8.53 million | Fiscal year 2021: -$8.83 million | Fiscal year 2020: -$19.89 million | Fiscal year 2019: -$20.45 million | Fiscal year 2018: -$3.09 million | Fiscal year 2017: -$6.6 thousand | Fiscal year 2016: -$1.00 million | Fiscal year 2015: -$11.74 million | Fiscal year 2014: -$3.98 million | Fiscal year 2013: -$94.4 thousand | Fiscal year 2012: -$98.1 thousand | Fiscal year 2011: -$99.7 thousand | Fiscal year 2010: $575.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: